Teva Pharmaceutical Industries confirmed that Eyal Desheh, group executive vice president, chief financial officer, will depart from Teva during the coming months. The company will immediately commence a search to identify a successor to serve as chief financial officer. Desheh will take part in the company’s upcoming Q1 earnings call on May 11th.
Desheh, 65, became group executive vice president, chief financial officer in 2008. From October 2013 to February 2014, Desheh served as acting president and chief executive officer. Earlier in his career, from 1989 to 1996, he served as Teva’s deputy chief financial officer.
Dr. Yitzhak Peterburg, interim president and CEO of Teva, stated, “Eyal has helped Teva grow into a leading global pharmaceutical company. The management team and I would like to thank Eyal for his many contributions, as well as his continued support during the transition.”
Eyal Desheh stated, “Yesterday, I celebrated my 65th birthday and I’m transitioning into the next phase of my career. It has been a privilege to serve for many years as Teva’s CFO alongside its exceptional management team and world-class employees. When I look back on my career with Teva, I am very proud of what we have accomplished as a company. I look forward to working to ensure a seamless transition as Teva continues executing for shareholders in 2017.”
Dr. Sol J. Barer, chairman of the board of directors, stated, “My highest priority is to identify and appoint Teva’s next chief executive officer. We expect the company’s new CEO to have a significant role in identifying Eyal’s successor.”